who shouldn't take tirzepatide Dosage Guide and Chart for Weight Loss Tirzepatide Eligibility: Who Shouldn't Use

BMS is foreshadowing a further decline in the upcoming years

Bujko, K

Based on the phase 2 and phase 3 trial protocols: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (maximum dose) The starting dose of retatrutide is deliberately low because the triple-agonist mechanism produces more intense initial side effects than single-pathway compounds

Anderson P, Saltin B: Maximal perfusion of skeletal muscle in man

Consuming alcohol with tirzepatide is not recommended because alcohol acts as a diuretic that also causes dehydration and electrolyte imbalances